This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Read More

Psoriatic Arthritis (PsA) Treatment Market

Psoriatic Arthritis (PsA) Treatment Market

Psoriatic Arthritis (PsA) Treatment Market

Psoriatic Arthritis (PsA) Treatment Market by Product (Non-steroidal Anti-inflammatory Drugs, Disease Modifying Anti-rheumatic Drugs, Biologics) & Region - Forecast 2022-2028

Psoriatic Arthritis (PsA) Treatment Market Outlook – 2022-2028

[193 Pages Report] Sales in the global Psoriatic Arthritis (PsA) Treatment Market are slated to top US$ 10.3 Bn in 2022. Expanding at a healthy 7.1% CAGR, the market size is projected to total US$ 15.6 Bn by 2028.

Attribute

Details

Psoriatic Arthritis (PsA) Treatment Market Estimated Size 2022

US$ 10.3 Bn 

Psoriatic Arthritis (PsA) Treatment Market Value-based CAGR (2022-2028)

~7.1%

Psoriatic Arthritis (PsA) Treatment Market Size in Projected 2028

US$ 15.6 Bn

The increasing need to prevent various effects of psoriatic arthritis, such as nail pitting, tender joints, flaky scalp, morning stiffness, painful muscles, and swollen fingers among the geriatric population, is anticipated to bolster the market in the upcoming years. In addition, the rising prevalence of this condition amongst those patients already suffering from plaque psoriasis is set to propel the sales in this market.

Besides, the easy availability of highly effective biological medicines for psoriasis, rapid adoption of hectic lifestyles leading to the overstimulation of the immune system, and increasing number of approvals of alternative therapies for psoriatic arthritis, are estimated to boost the market in the near future. Coupled with this, the emergence of online pharmacy solutions and telehealth facilities for getting one’s medications and prescriptions delivered at home is likely to augment the market.  

2013-2021 Psoriatic Arthritis (PsA) Treatment Market Outlook in Comparison to 2022-2028 Growth Forecast

The psoriatic arthritis (PsA) treatment market is expected to register 7.1% CAGR between 2022 and 2028, up from 6.7% CAGR recorded during 2013-2021, predicts Future Market Insights.

The consecutive launches and consistent developments of breakthrough products for rheumatoid psoriasis treatment are anticipated to drive the market in the near future. Various pharmaceutical companies are striving to enhance the efficacy and safety of their products owing to the implementation of stringent norms by the governments of various countries.

At the same time, the number of head-to-head trials between late-stage pipeline candidates, new drugs, and vital commercial products is likely to surge in the forthcoming years. This would further help in investigating the superiority of performance of numerous psoriatic medications through a comparative analysis of a large number of parameters.

Many academic and research institutions are also engaging in extensive research and development activities to unveil alternative therapies for psoriatic arthritis. For instance, in December 2021, researchers at Griffith University, Australia, found that upadacitinib has exhibited comparable safety and efficacy as monotherapy. It has also demonstrated superiority when used in combination with non-biologic disease-modifying antirheumatic drugs in patients living with psoriasis orthotics. The development of such novel treatment options by researchers and companies for psoriatic arthritis prevention is projected to support the growth in this market.

Which are the Factors Accelerating Development of Novel Psoriatic Medications?

The increasing life expectancy, genetic changes, higher prevalence of stressful lifestyles, and high geriatric population are set to propel the prevalence of psoriatic arthritis across the globe. Also, regulatory bodies in various countries are conducting awareness campaigns through social media platforms to make people better understand the importance of psoriatic arthritis prevention.

According to the World Health Organization (WHO), 1 in 6 people will be aged 60 years or above globally in 2030. In addition to this, the world’s population of people aged 60 years and older is expected to double by 2050 and reach 2.1 billion. This trend is set to continue, thereby creating new growth opportunities for pharmaceutical companies present in the field of psoriatic medications.

On top of that, psoriatic arthritis and psoriasis bone pain are often linked with depression and anxiety, which would enable companies to conduct R&D activities for coming up with new drugs. In April 2020, for instance, researchers at the Krembil Research Institute discovered that psoriatic arthritis and depression are closely related as depression can lead to inflammation and vice versa.

Patients with psoriatic arthritis have high levels of immune system proteins called cytokines that can trigger inflammation and lead to depression, whereas the inability of patients to perform their daily activities can result in depression. To prevent these conditions, various companies are expected to launch alternative therapies for psoriatic arthritis in the near future.

Country-wise Insights

What is the U.S. Psoriatic Arthritis (PsA) Treatment Market Outlook?

“Fast Track Approvals of Novel Psoriasis Orthotics Drugs to Bolster Growth”

The increasing demand for state-of-the-art psoriatic medications owing to the growing burden of the disease in the U.S. is projected to bolster the market in North America. As per the National Psoriasis Foundation, in the U.S., more than 8 million people suffer from psoriasis. In addition, if one parent has this disease, then a child has around a 10% chance of developing psoriasis. These numbers are set to continue in the forthcoming years, thereby driving the demand for psoriasis orthotics drugs.

Moreover, the rising R&D expenditure by key players, speedy approvals of biological medicines for psoriasis, and increasing government support to conduct clinical trials to discover novel treatment options for psoriatic arthritis prevention, are anticipated to boost the market in the U.S.

In December 2021, for instance, Amgen Inc., which is a reputed biopharmaceutical company based in California, bagged the U.S. FDA approval for the expanded usage of Otezla. It can now be used to treat adults with mild to moderate plaque psoriasis. The approval enabled the company to market Otezla as the only oral treatment option for adult patients. Spurred by the development of such innovative drugs for the treatment of psoriasis orthotics is likely to drive the market in the U.S.

Why is the U.K. Psoriatic Arthritis (PsA) Treatment Market Showcasing Robust Growth?

“Increasing Prevalence of Psoriasis Bone Pain to Drive the Market”

The rising cases of psoriasis bone pain among people in the U.K. is expected to augment the Europe market. To prevent such chronic effects of psoriatic arthritis, various drug manufacturers are anticipated to introduce unique treatment options in this country.

For instance, the U.K.’s National Institute for Health and Care Excellence (NICE) issued a Final Appraisal Determination (FAD) in January 2022, for recommending Rinvoq (upadacitinib) 15mg manufactured by AbbVie as a novel option for treating adult patients with active psoriatic arthritis. It can be used in combination with methotrexate or individually in these patients. Thus, the ongoing development and approval of new drugs to prevent psoriasis bone pain and other effects of psoriatic arthritis is set to accelerate the market in the U.K.

Which are the Factors Propelling China Psoriatic Arthritis (PsA) Treatment Market?

“Rising Prevalence of Obesity-induced Pustular Psoriasis Arthritis will Drive Market”

The surging prevalence of obesity is one of the crucial factors which is anticipated to drive the development of biological medicines for psoriasis in China. In December 2021, for instance, the country implemented its first guideline on physical activities, especially for citizens with chronic diseases to enhance the health of the entire population.

China's State Council had previously stated that more than 50% of adults in the country are overweight. The risk of pustular psoriasis arthritis is high in the obese population and thus the development of new drugs to prevent the severe effects of psoriatic arthritis is likely to surge in China.

The increasing smoking habit, high alcohol consumption, and adoption of unhealthy lifestyles are set to drive the market in this country. As per WHO, in 2016, in China, the total per capita consumption of alcohol was 17.0 liters among males and 6.0 liters in females. The prevalence of heavy episodic drinking was 60.8% in males and 24.9% among females above 15 years the same year. The consumption rate is expected to rise in the near future and increase the risk of pustular psoriasis arthritis among people in this country.

Category-wise Insights

Which is the Most Preferred Product in the Psoriatic Arthritis (PsA) Treatment Market?

“Patients are Preferring Non-steroidal Anti-inflammatory Drugs for Treating Psoriasis Orthotics”

Based on product, the non-steroidal anti-inflammatory drugs segment is set to dominate the psoriasis arthritis treatment market by generating the highest share in the near future. This growth is attributable to their increasing usage as an adjunct treatment in combination with disease-modifying antirheumatic drugs or biological medicines for psoriasis to cure severe cases.

Additionally, non-steroidal anti-inflammatory drugs are not recommended for patients suffering from chronic psoriasis as these can result in the occurrence of skin flare-ups. Thus, various drug manufacturing companies are anticipated to come up with new non-steroidal anti-inflammatory drugs with lesser side-effects, which would propel the segment.

Which is the Preferred Route of Administration for Psoriatic Arthritis (PsA) Treatment t?

“Injectables to Exhibit Steady Growth Backed by the Launch of Biologics for Pustular Psoriasis Arthritis”

By route of administration, the injectable segment is likely to account for 84.8% of the psoriasis arthritis treatment market share in 2022, predicts FMI. The increasing launch of biosimilars and biologics for the treatment of pustular psoriasis arthritis is anticipated to drive the growth of this segment in the forthcoming years.

Besides, injectables would help in controlling the skin involvement and inflammation in the affected joints for preventing disability and joint pain. Steroid injection is the most commonly used route of administration for rheumatoid psoriasis treatment.   

Which is the Dominant Distribution Channel in the Psoriatic Arthritis (PsA) Treatment Market?

“Hospital Pharmacies are Highly Preferred for Rheumatoid Psoriasis Treatment”

In terms of distribution channel, the hospital pharmacies segment is estimated to remain in the forefront in the psoriasis arthritis treatment market through 2028. The increasing number of hospitals across the globe is projected to drive this segment.

Furthermore, the availability of technologically advanced healthcare devices and medications in hospital pharmacies is surging their preference among patients for the management of critical conditions, such as rheumatoid psoriasis treatment. At the same time, the presence of skilled healthcare providers in these pharmacies is expected to drive the segment’s growth.

Competition Landscape

Key players operating in the market are striving to offer alternative therapies for psoriatic arthritis to cater to the high unmet needs. Some of the other players are collaborating with various government agencies to create awareness about psoriatic arthritis prevention among the general public. A few others are engaging in joint ventures, acquisitions, mergers, and collaborations to co-develop novel treatment options and gain fast track approval from the regulatory bodies.

For instance,

  • In December 2021, Novartis, a multinational pharmaceutical corporation based in Switzerland, received the US Food and Drug Administration (FDA) approval for Cosentyx (secukinumab). It will be used for the treatment of active psoriatic arthritis in patients belonging to the age group of two years and older, as well as enthesitis-related arthritis in patients four years and older. Cosentyx is considered to be the only biologic treatment approved by the FDA for the treatment of both active psoriatic and enthesitis-related arthritis in pediatric patients across the U.S.
  • In December 2021, AbbVie, a leading biopharmaceutical company headquartered in Illinois, bagged the U.S. FDA approval for Rinvoq for the treatment of psoriatic arthritis in adult patients who have failed at least one Tumor Necrosis Factor (TNF) inhibitor. The drug has proved to be a powerful treatment for the condition and this approval will help the company to strengthen its position in the market.

Scope of Report

Attribute

Details

Forecast Period

2013-2021

Historical Data Available for

2022-2028

Market Analysis

Units for Volume and US$ Bn for Value

Key Regions Covered

North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa.

Key Countries Covered

United States, Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Russia, Poland, China, India, Thailand, Indonesia, Australia and New Zealand, Japan, GCC countries, North Africa, South Africa, others.

Key Market Segments Covered

Product, Route of Administration, Distribution Channel, and Region

Key Companies Profiled

  • Pfizer Inc.
  • Johnson & Johnson
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • UCB S.A.
  • Eli Lilly & Co
  • Novartis AG
  • Celgene Corporation
  • AstraZeneca PLC

Pricing

Available upon Request

Sign Up with MarketNgage

World's Most Profilic Intelligence Engine

Get Access To The World's Largest Market Research Database.

Sign Up Now

Psoriatic Arthritis (PsA) Treatment Market by Category

Product Type:

  • Non-steroidal Anti-inflammatory Drugs
  • Disease Modifying Anti-rheumatic Drugs
    • Corticosteroids
    • Antimalarial
    • Methotrexate
    • Others
  • Biologics
    • TNF Inhibitors
    • Interleukin Inhibitors

Route of Administration:

  • Injectable
  • Oral

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail Order Pharmacies

Region:        

  • North America
  • Latin America
  • Europe
  • Oceania
  • East Asia
  • South Asia
  • Middle East & Africa (MEA)

Need specific information?

Our Clients

Healthcare

View All Reports from Healthcare

View Reports

Recommendations

Healthcare

Ophthalmic Eye Drops Market

Published : 2021-05-13

Healthcare

Pelvic Floor Stimulator Market

Published : 2021-07-19

Healthcare

Urinary Bag Market

Published : 2021-05-26

Healthcare

Pharmaceutical Caps And Closures Market

Published : 2021-05-27